| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0959-8049(00)00317-8 |
| P698 | PubMed publication ID | 11072213 |
| P2093 | author name string | M van Ballegooijen | |
| R Hermens | |||
| P433 | issue | 17 | |
| P921 | main subject | cervix uterine cancer | Q160105 |
| P304 | page(s) | 2244-2246 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Cervical cancer screening in the Netherlands | |
| P478 | volume | 36 |
| Q94468415 | A cross-sectional study of barriers to cervical cancer screening uptake in Ghana: An application of the health belief model |
| Q60949243 | Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing |
| Q33661393 | Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters |
| Q34433755 | Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system |
| Q84089766 | Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands |
| Q33732313 | Familial cervical cancer: case reports, review and clinical implications. |
| Q89687405 | HPV genotyping and p16/Ki-67 test significantly improve detection rate of high-grade cervical squamous intraepithelial lesion |
| Q77357831 | How do we decide at what age and at what frequency to screen for cancer of the cervix by cervical cytology? |
| Q81404025 | Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial |
| Q61626075 | Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial |
| Q35770411 | Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate |
| Q36671743 | Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area |
| Q35835177 | Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. |
| Q40026216 | Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis |
| Q36135525 | Patient satisfaction in treatment for cervical pathology |
| Q48503623 | Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India |
| Q36613522 | Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands |
| Q81816921 | Screening for cervical carcinoma |
| Q35587534 | The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. |
| Q35563325 | The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines |
| Q36135530 | Treatment strategies in intermediate cervical neoplasia: Implications of radical surgery |
| Q50733228 | Trends in incidence of and mortality from cancer in The Netherlands in the period 1989–1998 |
Search more.